BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou W, Lou W, Chen J, Ding B, Chen B, Xie H, Zhou L, Zheng S, Jiang D. AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest. Onco Targets Ther 2021;14:1049-59. [PMID: 33623392 DOI: 10.2147/OTT.S289324] [Reference Citation Analysis]
2 Chakraborty A, Roy S, Chakraborty MP, Roy SS, Purkait K, Koley TS, Das R, Acharya M, Mukherjee A. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation. Inorg Chem 2021;60:18379-94. [PMID: 34780170 DOI: 10.1021/acs.inorgchem.1c02979] [Reference Citation Analysis]
3 Zhang H, Xu H, Tang Q, Bi F. The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells. Anticancer Drugs 2021;32:793-801. [PMID: 33675613 DOI: 10.1097/CAD.0000000000001067] [Reference Citation Analysis]
4 Katoch S, Sharma V, Patial V. Peroxisome proliferator-activated receptor gamma as a therapeutic target for hepatocellular carcinoma: Experimental and clinical scenarios. World J Gastroenterol 2022; 28(28): 3535-3554 [DOI: 10.3748/wjg.v28.i28.3535] [Reference Citation Analysis]
5 Yasutomi E, Ueda Y, Asaji N, Yamamoto A, Yoshida R, Hatazawa Y, Hayashi H, Shiomi Y, Yano Y, Kodama Y. Liver abscess caused by Cutibacterium namnetense after transarterial chemoembolization for hepatocellular carcinoma. Clin J Gastroenterol 2021;14:246-50. [DOI: 10.1007/s12328-020-01283-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Deng LJ, Lei YH, Quan JY, Li BJ, Zhang DM, Tian HY, Chen Y, Zhang EX, Chen L, Ye WC, Ning WM, Yu LZ, Liu JS. 1β-OH-arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway. J Ethnopharmacol 2021;266:113443. [PMID: 33022344 DOI: 10.1016/j.jep.2020.113443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Contreras L, Rodríguez-gil A, Muntané J, de la Cruz J. Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells. Cancers 2022;14:1204. [DOI: 10.3390/cancers14051204] [Reference Citation Analysis]
8 Yan X, Tian R, Sun J, Zhao Y, Liu B, Su J, Li M, Sun W, Xu X. Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells. Front Pharmacol 2022;12:788667. [DOI: 10.3389/fphar.2021.788667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shen L, Zhou Y, He H, Chen W, Lenahan C, Li X, Deng Y, Shao A, Huang J. Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. Oxid Med Cell Longev 2021;2021:8865791. [PMID: 33628389 DOI: 10.1155/2021/8865791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
10 Liu J, Zhang SQ, Chen J, Li ZB, Chen JX, Lu QQ, Han YS, Dai W, Xie C, Li JC. Identifying Prognostic Significance of RCL1 and Four-Gene Signature as Novel Potential Biomarkers in HCC Patients. J Oncol 2021;2021:5574150. [PMID: 34257652 DOI: 10.1155/2021/5574150] [Reference Citation Analysis]
11 Al-Noshokaty TM, Mesbah NM, Abo-Elmatty DM, Abulsoud AI, Abdel-Hamed AR. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis. Life Sci 2022;303:120675. [PMID: 35640776 DOI: 10.1016/j.lfs.2022.120675] [Reference Citation Analysis]
12 Mroweh M, Roth G, Decaens T, Marche PN, Lerat H, Macek Jílková Z. Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. Int J Mol Sci 2021;22:1794. [PMID: 33670268 DOI: 10.3390/ijms22041794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Xu S, Ling S, Shan Q, Ye Q, Zhan Q, Jiang G, Zhuo J, Pan B, Wen X, Feng T, Lu H, Wei X, Xie H, Zheng S, Xiang J, Shen Y, Xu X. Self-Activated Cascade-Responsive Sorafenib and USP22 shRNA Co-Delivery System for Synergetic Hepatocellular Carcinoma Therapy. Adv Sci (Weinh) 2021;8:2003042. [PMID: 33717848 DOI: 10.1002/advs.202003042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
14 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, Payo-Serafín T, van Pelt J, Verslype C, González-Gallego J, Mauriz JL. Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. Int J Mol Sci 2021;22:11770. [PMID: 34769197 DOI: 10.3390/ijms222111770] [Reference Citation Analysis]
15 Xue C, Li G, Zheng Q, Gu X, Bao Z, Lu J, Li L. The functional roles of the circRNA/Wnt axis in cancer. Mol Cancer 2022;21:108. [PMID: 35513849 DOI: 10.1186/s12943-022-01582-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hu X, Zhu H, Shen Y, Zhang X, He X, Xu X. The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma. Front Oncol 2021;11:696705. [PMID: 34367979 DOI: 10.3389/fonc.2021.696705] [Cited by in F6Publishing: 1] [Reference Citation Analysis]